What is the therapeutic focus of Patrys’ (ASX:PAB) RLS-2202 drug candidate?

RLS-2202 is an experimental treatment engineered to address delirium in acute care settings, which management highlights as a critical, unmet medical need. The upcoming Phase 1A bridging study will test the drug in healthy volunteers to primarily assess its safety, tolerability, and pharmacokinetics.

Why are the appointments of CMAX and Alithia Life Sciences important for Patrys?

These appointments establish the essential operational framework required to advance RLS-2202 from pre-clinical stages into human clinical trials. Securing a trial site and a CRO means Patrys has the infrastructure ready to execute the trial as soon as regulatory approvals are granted.

How does this news change the investment thesis for Patrys (ASX:PAB) in the medium term?

This development transitions Patrys towards becoming a clinical-stage biotech company, which inherently alters its risk-reward profile for medium-term investors. Successful clinical entry typically increases valuation potential but also introduces clinical trial execution risks and data readout binary outcomes.

What are the main bull and bear points for Patrys (ASX:PAB) after this milestone?

The bull case is that Patrys is meeting its operational timelines and entering a market with high unmet need (delirium treatment) alongside experienced Phase 1 partners. The bear case is that the company remains pre-revenue, highly speculative, and entirely dependent on regulatory approvals and successful trial data to create long-term value.

What prior milestones led up to Patrys’ upcoming Phase 1A trial?

The appointment of CMAX and Alithia Life Sciences follows a series of manufacturing and regulatory de-risking activities that Patrys finalised in March 2026. Those foundational steps allowed the company to move forward with setting up the clinical framework for the drug candidate.

Image for illustrative purposes only. Not a real photo.

Patrys appoints partners for Phase 1A trial

Q: What did Patrys Limited (ASX:PAB) announce regarding its RLS-2202 program?

Patrys announced two key operational appointments for its upcoming Phase 1A clinical trial of RLS-2202. The company engaged CMAX as the dedicated clinical trial site to conduct its bridging study and selected Alithia Life Sciences as the Contract Research Organisation (CRO) to manage and execute the trial.

Written by Liezl GambePublished May. 20 2026

Biotech firm Patrys (ASX:PAB) announced two key appointments for its upcoming Phase 1A clinical trial of RLS-2202.

The company has engaged CMAX as the dedicated clinical trial site to conduct its bridging study, which will primarily assess the safety, tolerability, and pharmacokinetics of the therapeutic candidate in healthy volunteers.

Alithia Life Sciences has been appointed as the Contract Research Organisation to provide overarching clinical trial management and operational execution.

Selected through a competitive evaluation process, both organisations bring robust track records in delivering high-quality Phase 1 data and strict safety oversight.

The milestone establishes the essential operational framework for RLS-2202, a treatment engineered to address the critical, unmet medical need for delirium in acute care settings.

The development follows a series of manufacturing and regulatory de-risking activities finalised by Patrys in March.

Patrys' CEO, Dr Samantha South, expressed confidence in the partnerships, noting that the expertise of CMAX and Alithia is critical to advancing the programme towards first participant dosing.

Patrys is currently finalising its application for Human Research Ethics Committee approval, which it plans to submit in Q2 2026.

Pending the regulatory green light, the company remains firmly on track to commence participant dosing in Q3 2026.